01 November 2019 | Statements

Unitaid introduces its newest tuberculosis-fighting projects at Union World Conference

Hyderabad, India – Unitaid and partners launched a trio of innovations today that will work together to fight tuberculosis through gene-based diagnosis, better treatments and ingenious technologies that help patients remember to take their medicines.

The US$ 50 million in new investments was presented at the Union World Conference on Lung Health in India, confirming Unitaid’s position as the world’s largest multilateral funder of TB research and development. Unitaid’s TB portfolio has nearly doubled over the past few years and is on track to reach US$ 300 million in 2020.

TB kills about 1.5 million people a year.

Unitaid’s new projects attack the epidemic on three important fronts: diagnosis, treatment, and adherence, while working against drug-resistant infections. Drug-resistant TB poses a threat to the world’s gains against the epidemic.

“India, with the highest burden of TB globally, represents a fitting backdrop for launching Unitaid’s latest investments in the global response to end TB,” said Robert Matiru, Director of Programmes at Unitaid. “By attacking TB from multiple angles, these innovations are a promising, holistic response to the pressing need for new tools in this ancient fight”.

The projects are:

“Children have been largely neglected to date in the global response to MDR-TB and they deserve better. We are excited that, through Unitaid’s investment in this innovative project, Stellenbosch University and its partners can contribute to reduced morbidity and mortality in children by improving access to better, more child-friendly MDR-TB treatment and prevention,” said the project lead, Prof. Anthony Garcia-Prats from the Desmond Tutu TB Centre, Stellenbosch University and the University of Wisconsin-Madison.

“Digital adherence technologies empower patients, allowing them to take their medication at a time and place that suits them best and seek advice when they need it. At the same time, these technologies allow health care workers to better prioritize patients that need additional support”, said ASCENT project director Kristian van Kalmthout. “The project, which runs through 2022, will generate evidence, create a global market and engage stakeholders, including patients, to facilitate a global scale up that will benefit TB patients worldwide. This can ultimately contribute to reducing global TB incidence, drug resistance and mortality,” he added.

“The Seq&Treat project aims to help patients get a fast, reliable TB diagnosis, ensuring that they can be linked to the most appropriate treatment as soon as possible. Long term, this approach should lead to a decrease in the transmission of drug-resistant TB. Unitaid’s significant investment and FIND’s expertise will allow us to demonstrate sustainable and scalable sequencing models in high-burden TB countries – and serve as a pathfinder to expand sequencing applications to AMR and beyond,” said FIND CEO Catharina Boehme.

Check out our web page:


For media enquiries:

Priyamvada Chugh, chughp@unitaid.who.int

View All News

Featured News

04 December 2019

Unitaid seeks proposals to expand malaria chemoprevention for infants, following new WHO report

Read More

29 November 2019

Unitaid celebrates HIV milestones and explores cutting-edge medicines and tests

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.